retatrutide phase 2 results obesity nejm 2023 🤔 Adults with type diabetes (T2D) and lose less weight on EVERY GLP-1 drug compared to those without diabetes, consistently ~5% less. Now that we have retatrutide's TRIUMPH-2 data today Retatrutide vs Semaglutide: Triple vs

The range in clinical trials runs from about 25% to 40%, depending on the drug, dose, duration, and whether participants were exercising and eating adequate protein

Categories such as snacking are seeing particular impact, with chocolate confectionery expenditure declining 18% more among GLP-1 users than among non-user households

Both are GLP-1 receptor agonists initially developed for type 2 diabetes management but have shown significant benefits in weight reduction

Applications Retatrutide has a broad array of applications, primarily in the treatment of metabolic disorders

GLP-1 drugs can only be prescribed to people after meeting stringent regulatory standards set by agencies like the FDA

GLP-1 medications arent a quick fix theyre meant to be taken long-term even if you reach your A1c and weight loss goals